Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.140
+0.040 (3.64%)
At close: Jul 21, 2026, 4:00 PM EDT
1.140
0.00 (0.00%)
After-hours: Jul 21, 2026, 5:10 PM EDT

Lineage Cell Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
284406111191199415
Market Cap Growth
29.65%266.57%-41.93%-4.16%-52.07%54.10%
Enterprise Value
229.47351.4564.1156.8143.63358.34
Last Close Price
1.141.670.501.091.172.45
Forward PE
-45.6245.6245.6245.6245.62
PS Ratio
18.9827.8911.6621.3213.5495.65
PB Ratio
5.099.111.413.012.714.50
P/TBV Ratio
23.68176.524.7530.4312.4411.61
P/FCF Ratio
----308.06-
P/OCF Ratio
----187.92-
EV/Sales Ratio
15.5324.146.7517.539.7782.55
EV/FCF Ratio
----222.33-
Debt / Equity Ratio
0.030.040.020.030.040.02
Debt / FCF Ratio
----6.03-
Net Debt / Equity Ratio
-0.95-1.20-0.58-0.51-0.74-0.60
Net Debt / EBITDA Ratio
1.381.492.171.352.481.15
Net Debt / FCF Ratio
2.262.751.911.11-83.562.32
Asset Turnover
0.130.130.090.080.100.03
Quick Ratio
6.654.993.472.023.062.32
Current Ratio
6.895.203.652.143.162.37
Return on Equity (ROE)
-133.30%-105.30%-26.73%-32.07%-32.37%-46.52%
Return on Assets (ROA)
-33.95%-29.94%-20.05%-20.31%-15.42%-34.84%
Return on Invested Capital (ROIC)
--311.47%-70.19%-96.20%-86.28%-106.74%
Return on Capital Employed (ROCE)
-37.22%-36.54%-23.56%-26.35%-19.40%-43.24%
FCF Yield
----0.32%-
Buyback Yield / Dilution
-11.32%-14.95%-15.94%-1.69%-3.22%-9.64%
Total Shareholder Return
-11.32%-14.95%-15.94%-1.69%-3.22%-9.64%
SEC Filings: 10-K · 10-Q